PLN Reaffirms Commitment to Advancing a Just Energy Transition at COP30
Kyrgyz Republic Launches First Issuance of Gold-Backed Stablecoin USDKG
OMP Miami Conference 2025: Transforming Supply Chain Vision into REAL Impact with Human-AI Synergy
Doubleview Gold Corp. Highlights Scandium Potential at Hat Project, a Key Enabler for the Electrification Economy
U.S. Polo Assn. Receives Multiple Global Honors Recognizing Excellence in Brand, Content, and Digital Growth
Topline data expected in 2024 MIAMI, July 27, 2023 (GLOBE NEWSWIRE) — Avenue Therapeutics, Inc….
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a…
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology…
Combined company to operate as Ayala Pharmaceuticals, Inc. Merger to add a clinical stage oncology…
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company…
SEATTLE , July 27, 2023 (GLOBE NEWSWIRE) — Avalyn Pharma Inc., a clinical-stage biopharmaceutical company…
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date…
Phase 1-ready device shows 100% success in human functional study of twelve subjects to date…
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of…
The Phase 2 TAHOE study, which is currently enrolling, evaluates the safety and efficacy of…
ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company”…
ASHBURN, Va., July 27, 2023 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company”…
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023…
Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif., July 27, 2023…
NEW YORK and LONDON, July 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
NEW YORK and LONDON, July 27, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX),…
Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a…
Dr. Bronstein, the DeepMind Professor of AI at Oxford, will help VantAI unlock the potential…
Preliminary data suggest a chlamydia, gonorrhea and trichomonas (CT/NG/TV) multiplex test is feasible on a…